Perfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Claire Drigotas
Division of Surgical Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for more papers by this authorAlexander W. Loftus
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorJohn B. Ammori
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorLuke D. Rothermel
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Richard S. Hoehn
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Correspondence: Richard S. Hoehn ([email protected])
Search for more papers by this authorClaire Drigotas
Division of Surgical Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for more papers by this authorAlexander W. Loftus
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorJohn B. Ammori
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorLuke D. Rothermel
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Richard S. Hoehn
Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
Correspondence: Richard S. Hoehn ([email protected])
Search for more papers by this authorMeeting presentations: Case Western Reserve University School of Medicine Graduate and Medical Student Research Day; Cleveland, OH (2023). University Hospitals Department of Surgical Research Day; Cleveland OH (2024).
ABSTRACT
Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to chemotherapeutic agent, dose, administration temperature, or duration and limited literature comparing outcomes in different regimens. In this study, we analyze common practices and outcomes of published HIPEC regimens to gain insight into current practice to inform future directions of study. We conducted a literature search for investigational studies of CRS and HIPEC for MPM treatment in adults and identified 35 such articles. These studies were analyzed for institution type and location, drug regimens, perfusion temperatures and time, and study outcomes including median survival, complication rates, and perioperative mortality rates. On review, there is significant heterogeneity in HIPEC regimens and outcome reporting metrics, suggesting a need for multi-institutional standardized study protocols to better determine the safest and most efficacious treatment regimen.
Open Research
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in the study.
References
- 1B. Price, “Analysis of Current Trends in United States Mesothelioma Incidence,” American Journal of Epidemiology 145, no. 3 (February 1997): 211–218, https://doi.org/10.1093/oxfordjournals.aje.a009093.
- 2S. H. Moolgavkar, R. Meza, and J. Turim, “Pleural and Peritoneal Mesotheliomas in SEER: Age Effects and Temporal Trends, 1973–2005,” Cancer Causes & Control 20, no. 6 (August 2009): 935–944, https://doi.org/10.1007/s10552-009-9328-9.
- 3T. D. Yan, M. Deraco, D. Elias, et al., “A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of a Multi-Institutional Database,” Cancer 117, no. 9 (May 2011): 1855–1863, https://doi.org/10.1002/cncr.25640.
- 4A. García-Fadrique, A. Mehta, F. Mohamed, S. Dayal, T. Cecil, and B. J. Moran, “Clinical Presentation, Diagnosis, Classification and Management of Peritoneal Mesothelioma: A Review,” Journal of Gastrointestinal Oncology 8, no. 5 (October 2017): 915–924, https://doi.org/10.21037/jgo.2017.08.01.
- 5A. Bridda, I. Padoan, R. Mencarelli, and M. Frego, “Peritoneal Mesothelioma: A Review,” MedGenMed 9, no. 2 (May 2007): 32.
- 6J. H. Helm, J. T. Miura, J. A. Glenn, et al., “Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-Analysis,” Annals of Surgical Oncology 22, no. 5 (May 2015): 1686–1693, https://doi.org/10.1245/s10434-014-3978-x.
- 7V. Verma, R. L. Sleightholm, C. G. Rusthoven, et al., “Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival,” Annals of Surgical Oncology 25, no. 7 (July 2018): 2018–2026, https://doi.org/10.1245/s10434-018-6499-1.
- 8 Chicago Consensus Working Group, “The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma,” Annals of Surgical Oncology 27, no. 6 (2020): 1774–1779, https://doi.org/10.1245/s10434-020-08324-w.
- 9A. U. Blackham, P. Shen, J. H. Stewart, G. B. Russell, and E. A. Levine, “Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin,” Annals of Surgical Oncology 17, no. 10 (October 2010): 2720–2727, https://doi.org/10.1245/s10434-010-1080-6.
- 10B. Malgras, E. Gayat, O. Aoun, et al., “Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study,” Annals of Surgical Oncology 25, no. 11 (October 2018): 3271–3279, https://doi.org/10.1245/s10434-018-6631-2.
- 11E. Bekhor, J. Carr, M. Hofstedt, et al., “The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis,” Annals of Surgical Oncology 27, no. 5 (May 2020): 1448–1455, https://doi.org/10.1245/s10434-019-08141-w.
- 12C. D. Valenzuela, I. B. Solsky, R. A. Erali, et al., “Long-Term Survival in Patients Treated With Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center,” Annals of Surgical Oncology 30, no. 5 (May 2023): 2666–2675, https://doi.org/10.1245/s10434-022-13061-3.
- 13N. P. Schaub, M. Alimchandani, M. Quezado, et al., “A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival,” Annals of Surgical Oncology 20, no. 2 (February 2013): 555–561, https://doi.org/10.1245/s10434-012-2651-5.
- 14H. R. Alexander, D. L. Bartlett, J. F. Pingpank, et al., “Treatment Factors Associated With Long-Term Survival After Cytoreductive Surgery and Regional Chemotherapy for Patients With Malignant Peritoneal Mesothelioma,” Surgery 153, no. 6 (June 2013): 779–786, https://doi.org/10.1245/s10434-017-5834-2.
- 15V. Kepenekian, D. Elias, G. Passot, et al., “Diffuse Malignant Peritoneal Mesothelioma: Evaluation of Systemic Chemotherapy With Comprehensive Treatment Through the RENAPE Database,” European Journal of Cancer 65 (September 2016): 69–79, https://doi.org/10.1245/s10434-017-5834-2.
- 16Y. C. Li, T. Khashab, J. Terhune, et al., “Preoperative Thrombocytosis Predicts Shortened Survival in Patients With Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy,” Annals of Surgical Oncology 24, no. 8 (August 2017): 2259–2265, https://doi.org/10.1245/s10434-017-5834-2.
- 17M. Deraco, D. Nonaka, D. Baratti, et al., “Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion,” Annals of Surgical Oncology 13, no. 2 (February 2006): 229–237, https://doi.org/10.1245/ASO.2006.03.045.
- 18R. Shamavonian, E. Cheng, J. B. Karpes, S. Barat, N. Ahmadi, and D. L. Morris, “Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre,” Anticancer Research 42, no. 6 (June 2022): 2939–2944, https://doi.org/10.1016/j.suronc.2014.12.002.
- 19J. Hubert, E. Thiboutot, P. Dubé, A.-S. Cloutier, P. Drolet, and L. Sideris, “Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin for Peritoneal Mesothelioma: Preliminary Results and Survival Analysis,” Surgical Oncology 24, no. 1 (March 2015): 41–46, https://doi.org/10.1016/j.suronc.2014.12.002.
- 20Y.-D. Su, Z.-R. Yang, X.-B. Li, Y. Yu, X.-M. Du, and Y. Li, “Key Factors for Successful Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy to Treat Diffuse Malignant Peritoneal Mesothelioma: Results From Specialized Peritoneal Cancer Center in China,” International Journal of Hyperthermia 39, no. 1 (December 2022): 706–712, https://doi.org/10.1080/02656736.2022.2066728.
- 21M. Acs, M. Gerken, I. Gajic, M. Mayr, J. Zustin, and P. Piso, “Ten-Year Single-Center Experience With Treatment of Primary Diffuse Malignant Peritoneal Mesothelioma (DMPM) by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC),” Langenbeck's Archives of Surgery 407, no. 7 (June 2022): 3057–3067, https://10.1007/s00423-022-02594-6.
- 22S. N. S. Gilani, A. Mehta, A. Garcia-Fadrique, et al., “Outcomes of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma and Predictors of Survival,” International Journal of Hyperthermia 34, no. 5 (July 2018): 578–584, https://doi.org/10.1080/02656736.2018.1434902.
- 23M. Robella, M. Vaira, A. Cinquegrana, and M. De Simone, “Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Morbidity and Postoperative Outcomes,” Minerva Chirurgica 74, no. 3 (May 2019): 195–202, https://doi.org/10.23736/S0026-4733.18.07649-6.
- 24M. Robella, M. Vaira, A. Mellano, et al., “Treatment of Diffuse Malignant Peritoneal Mesothelioma (DMPM) by Cytoreductive Surgery and HIPEC,” Minerva Chirurgica 69, no. 1 (February 2014): 9–15.
- 25T. C. Chua, T. D. Yan, and D. L. Morris, “Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: The Australian Experience,” Journal of Surgical Oncology 99, no. 2 (February 2009): 109–113, https://doi.org/10.1002/jso.21177.
- 26A. Saxena and T. C. Chua, “Results of Systemic Pemetrexed-Based Combination Chemotherapy Versus Cytoreductive Surgery and Hyperthermic Intraperitoneal Cisplatin and Doxorubicin on Survival in Malignant Peritoneal Mesothelioma,” Lung Cancer 66, no. 2 (November 2009): 269–270, https://doi.org/10.1016/j.lungcan.2009.08.007.
- 27T. C. Chua, T. D. Yan, M. Deraco, O. Glehen, B. J. Moran, and P. H. Sugarbaker, “Multi-Institutional Experience of Diffuse Intra-Abdominal Multicystic Peritoneal Mesothelioma,” British Journal of Surgery 98, no. 1 (December 2010): 60–64, https://doi.org/10.1002/bjs.7263.
- 28K. Stamou, D. Tsamis, N. Pallas, et al., “Treating Peritoneal Mesothelioma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. A Case Series and Review of the Literature,” International Journal of Hyperthermia 31, no. 8 (2015): 850–856, https://doi.org/10.3109/02656736.2015.1075071.
- 29D. Elias, V. Bedard, T. Bouzid, et al., “Malignant Peritoneal Mesothelioma: Treatment With Maximal Cytoreductive Surgery Plus Intraperitoneal Chemotherapy,” Gastroentérologie Clinique et Biologique 31, no. 10 (October 2007): 784–788, https://doi.org/10.1016/S0399-8320(07)73964-7.
- 30C. Brigand, O. Monneuse, F. Mohamed, et al., “Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study,” Annals of Surgical Oncology 13, no. 3 (March 2006): 405–412, https://doi.org/10.1245/ASO.2006.05.041.
- 31M. Deraco, P. Casali, M. G. Inglese, et al., “Peritoneal Mesothelioma Treated by Induction Chemotherapy, Cytoreductive Surgery, and Intraperitoneal Hyperthermic Perfusion,” Journal of Surgical Oncology 83, no. 3 (July 2003): 147–153, https://doi.org/10.1002/jso.10255.
- 32H. Yano, B. J. Moran, T. D. Cecil, and E. M. Murphy, “Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Mesothelioma,” European Journal of Surgical Oncology 35, no. 9 (September 2009): 980–985, https://doi.org/10.1016/j.ejso.2008.09.010.
- 33A. Zahid, L. Clarke, N. Carr, et al., “Outcomes of Multicystic Peritoneal Mesothelioma Treatment With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy,” BJS Open 5, no. 2 (March 2021): zraa001, https://doi.org/10.1093/bjsopen/zraa001.
- 34R. Nassabein, R. Younan, R. Loungarath, et al., “A Canadian Single-Centre Experience With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Abdominal Malignancies,” Canadian Journal of Surgery 65, no. 3 (May 2022): E342–E351, https://doi.org/10.1503/cjs.004320.
- 35D. R. Heller, C. Chiuzan, R. N. Taub, et al., “Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma With Cytoreduction and Heated Intraperitoneal Chemotherapy,” Annals of Surgical Oncology 24, no. 13 (December 2017): 3818–3824, https://doi.org/10.1245/s10434-017-6106-x.
- 36X. Wang, S. Katz, J. Miura, et al., “A Single-Center Retrospective Cohort Study of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma,” PLoS One 17, no. 9 (2022): e0275187, https://doi.org/10.1245/s10434-008-0219-1.
- 37D. Baratti, S. Kusamura, A. D. Cabras, P. Dileo, B. Laterza, and M. Deraco, “Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC),” Annals of Surgical Oncology 16, no. 2 (February 2009): 463–472, https://doi.org/10.1245/s10434-008-0219-1.
- 38T. Wang, H. Li, B. Ye, and D. Zhang, “Value of Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy to Treat Malignant Peritoneal Mesothelioma,” American Journal of Translational Research 13, no. 9 (2021): 10712–10720.
- 39N. Aydin, A. Sardi, V. Milovanov, et al., “Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center,” American Surgeon 81, no. 12 (December 2015): 1253–1259.
- 40G. H. Tan, M. Cheung, J. Chanyaputhipong, K. C. Soo, and M. C. Teo, “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma,” Annals of the Academy of Medicine, Singapore 42, no. 6 (June 2013): 291–296.
- 41Y. Yonemura, H. Ishibashi, E. Canbay, et al., “Treatment Results of Diffuse Malignant Peritoneal Mesothelioma,” Gan To Kagaku Ryoho 39, no. 12 (November 2012): 2416–2419.
- 42D. Costamagna, S. Scuderi, M. Vaira, R. Barone, and M. De Simone, “Treatment of Peritoneal Mesothelioma Using Cytoreduction and Intraperitoneal Hyperthermic Chemotherapy,” supplement, Tumori 89, no. S4 (2003): 40–42.
- 43S. J. Shetty, L. Bathla, V. Govindarajan, P. Thomas, and B. W. Loggie, “Comparison of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin or Carboplatin for Diffuse Malignant Peritoneal Mesothelioma,” American Surgeon 80, no. 4 (2014): 348–352.
- 44D. Baratti, S. Kusamura, A. D. Cabras, R. Bertulli, I. Hutanu, and M. Deraco, “Diffuse Malignant Peritoneal Mesothelioma: Long-Term Survival With Complete Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC),” European Journal of Cancer, 49, no. 15 (October 2013): 3140–3148, https://doi.org/10.1016/j.ejca.2013.05.027.
- 45V. Kepenekian, O. Sgarbura, F. Marchal, L. Villeneuve, S. Kusamura, and M. Deraco, “2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma,” Annals of Surgical Oncology 30, no. 12 (November 2023): 7803–7813, https://doi.org/10.1245/s10434-023-13973-8.